Dipyridamole label

Dipyridamole

Dipyridamole Recall

Get an alert when a recall is issued.

Side Effects & Adverse Reactions

There is currently no warning information available for this product. We apologize for any inconvenience.

Legal Issues

There is currently no legal information available for this drug.

FDA Safety Alerts

There are currently no FDA safety alerts available for this drug.

Manufacturer Warnings

There is currently no manufacturer warning information available for this drug.

FDA Labeling Changes

There are currently no FDA labeling changes available for this drug.

Uses

Dipyridamole Tablets, USP are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement.

History

There is currently no drug history available for this drug.

Other Information

Dipyridamole, USP is a platelet inhibitor chemically described as 2,2′,2”,2”’-[(4,8-Dipiperidinopyrimido[5,4-d]pyrimidine-2,6-diyl)dinitrilo]-tetraethanol. It has the following structural formula:

dipyridamole-molec-structure

Dipyridamole is an odorless yellow crystalline powder, having a bitter taste. It is soluble in dilute acids, methanol and chloroform, and practically insoluble in water.

Dipyridamole Tablets USP, 25 mg, 50 mg and 75 mg for oral administration contain 25 mg, 50 mg, and 75 mg of dipyridamole, USP, respectively.

Inactive ingredients for Dipyridamole Tablets USP, 25 mg, 50 mg, and 75 mg: microcrystalline cellulose, povidone, crospovidone, lactose monohydrate, colloidal silicon dioxide, magnesium stearate, FD&C Red # 40 aluminum lake, FD&C Yellow #6 aluminum lake, lecithin, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.

Navigate to :

Dipyridamole Recall

Side Effects & Adverse Reactions

FDA Safety Alerts

Manufacturer Warnings

FDA Labeling Changes

Other Information

Trending Topics

Dipyridamole Manufacturers

Lannett Company, Inc.
No Recall
Dipyridamole | Lannett Company, Inc.
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement

The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Cadila Healthcare Limited
No Recall
Dipyridamole | Cadila Healthcare Limited
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement:

The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Zydus Pharmaceuticals (Usa) Inc.
No Recall
Dipyridamole | Zydus Pharmaceuticals (usa) Inc.
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement:
The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
West-ward Pharmaceutical Corp.
No Recall
Dipyridamole | West-ward Pharmaceutical Corp.
The dose of intravenous Dipyridamole Injection as an adjunct to thallium myocardial perfusion imaging should be adjusted according to the weight of the patient. The recommended dose is 0.142 mg/kg/min (0.57 mg/kg total) infused over 4 minutes. Although the maximum tolerated dose has not been determined, clinical experience suggests that a total dose beyond 60 mg is not needed for any patient.
Prior to intravenous administration, Dipyridamole Injection should be diluted in at least a 1:2 ratio with sodium chloride injection 0.45%, sodium chloride injection 0.9% or dextrose injection 5% for a total volume of approximately 20 to 50 mL. Infusion of undiluted dipyridamole may cause local irritation.

Thallium-201 should be injected within 5 minutes following the 4-minute infusion of dipyridamole.

Do not mix Dipyridamole Injection with other drugs in the same syringe or infusion container.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
General Injectables & Vaccines, Inc
No Recall
Dipyridamole | General Injectables & Vaccines, Inc
The dose of intravenous Dipyridamole Injection as an adjunct to thallium myocardial perfusion imaging should be adjusted according to the weight of the patient. The recommended dose is 0.142 mg/kg/min (0.57 mg/kg total) infused over 4 minutes. Although the maximum tolerated dose has not been determined, clinical experience suggests that a total dose beyond 60 mg is not needed for any patient.
Prior to intravenous administration, Dipyridamole Injection should be diluted in at least a 1:2 ratio with sodium chloride injection 0.45%, sodium chloride injection 0.9% or dextrose injection 5% for a total volume of approximately 20 to 50 mL. Infusion of undiluted dipyridamole may cause local irritation. Thallium-201 should be injected within 5 minutes following the 4-minute infusion of dipyridamole. Do not mix Dipyridamole Injection with other drugs in the same syringe or infusion container.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.
Roxane Laboratories, Inc.
No Recall
Dipyridamole | Roxane Laboratories, Inc.
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement. The recommended dose is 75-100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Anazaohealth Corporation
No Recall
Dipyridamole | Anazaohealth Corporation
The recommended dose is 0.142 mg/kg/minute (0.57 mg/kg total) or 0.568 mg/kg or 60 mg total dose infused over 4 minutes. Although the maximum tolerated dose has not been determined, clinical experience suggests that a total dose beyond 60 mg is not needed for any patient.

Prior to intravenous administration, dipyridamole should be diluted in at least a 1:2 ratio with 0.45% sodium chloride injection, 0.9% sodium chloride injection, or 5% dextrose injection for a total volume of approximately 20 to 50 mL. Infusion of undiluted dipyridamole injection may cause local irritation.

Myocardial perfusion assessment should be started when maximal vasodilation is reached, usually after 3 minutes, which generally occurs approximately 7 minutes from onset of infusion
Rising Pharmaceuticals, Inc.
No Recall
Dipyridamole | Rising Pharmaceuticals, Inc.
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement. The recommended dose is 75 mg to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Ncs Healthcare Of Ky, Inc Dba Vangard Labs
No Recall
Dipyridamole | Ncs Healthcare Of Ky, Inc Dba Vangard Labs
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement:
The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Avkare, Inc.
No Recall
Dipyridamole | Avkare, Inc.
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement. The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Cardinal Health
No Recall
Dipyridamole | Cardinal Health
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement. The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Cardinal Health
No Recall
Dipyridamole | Cardinal Health
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement.
The recommended dose is 75-100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Barr Laboratories Inc.
No Recall
Dipyridamole | Barr Laboratories Inc.
Adjunctive Use In Prophylaxis Of Thromboembolism After Cardiac Valve Replacement
The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Major Pharmaceuticals
No Recall
Dipyridamole | Major Pharmaceuticals
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement.
The recommended dose is 75-100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Global Pharmaceuticals, Division Of Impax Laboratories Inc.
No Recall
Dipyridamole | Global Pharmaceuticals, Division Of Impax Laboratories Inc.
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement
The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.
Avpak
No Recall
Dipyridamole | Avpak
Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement. The recommended dose is 75 to 100 mg four times daily as an adjunct to the usual warfarin therapy. Please note that aspirin is not to be administered concomitantly with coumarin anticoagulants.